Clinical Trial

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

Name: Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. — clinical trial record (NCT07518329)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SAPPHIRE

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101

Trial Details

NCT Number	NCT07518329
Lead Sponsor	Arovella Therapeutics Ltd
Conditions	Non Hodgkin Lymphoma (NHL), Leukaemia
Enrollment	46 participants
Start Date	2026-08-20
Primary Completion	2030-03-31 (estimated)
Study Completion	2030-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-06